Pharmaceuticals, Biotechnology and Life Sciences
Longest survival follow-up from a pooled analysis of randomized Phase 3 trials of an Immuno-Oncology therapy in this setting demonstrated…
Study Met Its Co-Primary Endpoint of Overall Survival with Opdivo® (nivolumab) Plus Low Dose Yervoy® (ipilimumab) vs. Chemotherapy in First-Line Non-Small Cell Lung Cancer Patients Whose Tumors Express PD-L1 ≥1%
Bayer, Bristol-Myers Squibb Company (NYSE: BMY) and Ono Pharmaceutical Co., Ltd. (“Ono”) announced today the three companies have entered into a clinical collaboration agreement to evaluate the combination of Bayer’s kinase inhibitor Stivarga® (regorafenib) and Bristol-Myers Squibb’s / Ono’s anti-PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab) in patients with micro-satellite stable metastatic colorectal cancer (MSS mCRC), the most common form of mCRC.1
Taris Bio has dosed the first patient in a test of its investigational product TAR-200 combined with Bristol-Myers Squibb’s Opdivo.
DUBLIN–(BUSINESS WIRE)–The “Opdivo” drug pipelines has been added to ResearchAndMarkets.com’s offering. Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) is a fully human…
Analyses include the longest follow-up of lung cancer patients treated with Immuno-Oncology therapy in phase 3 randomized trials PRINCETON, N.J.–(BUSINESS…
Mirati Therapeutics and Bristol-Myers Squibb will work together on evaluating the combination of sitravatinib and nivolumab (OPDIVO), in Mirati’s planned Phase 3 trial in second line non-small cell lung cancer (NSCLC) patients who have progressed following treatment with a platinum-based regimen and a checkpoint inhibitor.
Bristol-Myers Squibb said on Monday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…
Bristol-Myers Squibb Company today said that new data from a cohort of the phase 2 CheckMate -142 test of the…
The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on three Opdivo-based combination clinical studies in…